Merck & Co's Keytruda fails in first line bladder cancer

Merck & Co’s bid to become standard care in untreated bladder cancer has run into trouble after its Keytruda failed to outperform chemotherapy in this lucrative indication. 

ASCO 2020 round-up: Virtual conference still delivers the dr...

ASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping moments, reports Richard Staines. This time of year oncologists from

Merck & Co's Keytruda outperforms chemo in MSI-High colorect...

Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, offering patients a single-agent therapy opt

Merck & Co squares up to Roche with Keytruda data in triple-...

Roche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe not for long after Merck & Co reported good

Merck builds case for six-week Keytruda dosing as FDA starts...

FDA reviews Merck & Co's Keytruda in new 'tumour agnostic' u...

Merck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use in all cancer patients whose tumours have a certain genetic biomarker.